NewsShowing 1 to 5 of 28 results
As we learn about life with COVID-19, the scientific community is working to develop better solutions. The development of treatments has improved the prevention of complications that can lead to hospitalization. In this presentation, Marc Geirnaert, Director of the Provincial Oncology Drug Program at CancerCare Manitoba, discusses the latest protective treatments available in Canada to prevent hospitalizations.
The Leukemia and Lymphoma Society of Canada (LLSC) is always looking for ways to connect with our blood cancer community, and one of the many ways we do this is through meaningful partnerships. Jacquie Rowe is a reclaimed wood artist living in Ontario, currently living with blood cancer. The LLSC has helped Jacquie throughout her diagnosis, and is proud to partner with her business, Lumberjacq, as a retail partner. Alongside her wood working artworks, Jacquie sells clothing with proceeds going towards the LLSC. Read about Jacquie’s journey with Lumberjacq below.
Barriers and vaccination remain the best means of preventing COVID-19 infection and complications. However, some patients with a hematological cancer are unlikely to have an effective immune response. Passive immunity through SARS-CoV-2 neutralizing antibodies is one way to provide additional protection to individuals with compromised immunity or those at high risk of COVID-19 complications.
The Leukemia & Lymphoma Society of Canada has worked tirelessly to help Canadians affected by a blood cancer to make informed choices about how to protect themselves from the effects of COVID-19. As we adapt to a life after COVID and pandemic restrictions, LLSC encourages everyone to respect and protect each other.